Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces Closing of UNIT Private Placement

Newsfile June 22, 2022

Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01

Newsfile June 14, 2022

Hemostemix (TSXV:HEM) announces non-brokered private placement

John Ballem  May 20, 2022

Hemostemix Announces Financing

Newsfile May 19, 2022

Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations

Newsfile May 19, 2022

Hemostemix Announces Rick Groome as Special Advisor to The CEO

Newsfile May 16, 2022

Hemostemix Announces Its Intellectual Property is Back Home

Newsfile May 10, 2022

Hemostemix Inc. (TSXV:HEM) closes $2.75M non-brokered debenture offering

John Ballem  April 25, 2022

Hemostemix Announces Closing of $2,750,000

Newsfile April 25, 2022

Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed

Newsfile April 12, 2022

Hemostemix Announces Settlement Agreement

Newsfile March 23, 2022

Hemostemix: Interest Payment on Convertible Debenture

Newsfile March 3, 2022

Hemostemix Announces $2,750,000 Convertible Debenture

Newsfile March 2, 2022

Hemostemix Announces Stock Options Grant

Newsfile March 1, 2022

Hemostemix Announces Closing of UNIT Private Placement

Newsfile February 28, 2022

Your Fountain of Youth trademarked by Hemostemix (TSXV:HEM)

Brieanna McCutcheon  February 14, 2022

Your Fountain of Youth Trademarked by Hemostemix

Newsfile February 14, 2022

Today’s market summary: oil and big tech set February pace

Trevor Abes  February 2, 2022

Hemostemix (TSXV:HEM) announces $1M private placement

John Ballem  February 2, 2022

Hemostemix Announces Financing

Newsfile February 2, 2022